empagliflozin / linagliptin

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Glyxambi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Glyxambi.

For practical information about using Glyxambi, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 27/09/2023

Authorisation details

Product details
Agency product number
Active substance
  • empagliflozin
  • linagliptin
International non-proprietary name (INN) or common name
  • empagliflozin
  • linagliptin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Boehringer Ingelheim International GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Binger Strasse 173 55216
Ingelheim am Rhein

Product information

30/08/2023 Glyxambi - EMEA/H/C/003833 - WS2450/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

  • to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;
  • when already being treated with the free combination of empagliflozin and linagliptin.

Assessment history

How useful was this page?

Add your rating
3 ratings
6 ratings
1 rating